Undisclosed (Platform-derived)

About Libera Bio

Libera Bio is a private, preclinical-stage biotech focused on overcoming the challenge of 'undruggable' intracellular targets in oncology. Its core asset is the patented MPN Technology®, a nanotechnology platform designed to encapsulate and deliver biologics, such as monoclonal antibodies, and small molecules directly into cancer cells. The company is advancing its pipeline through internal efforts and strategic collaborations, operates a partnership-driven business model, and is supported by seed funding and public grants as it works towards clinical development.

Therapeutic Areas